武汉大学人民医院湖北省人民医院

院内导航

成薇婷肿瘤
副主任医师，硕士生导师

A+ A-

导师介绍

姓名	成薇婷
出生年月	1980.3.
单位	武汉大学人民医院肿瘤科
所属学科	临床医学-肿瘤学
职务、职称及头衔	副主任医师，硕士生导师
E-mail	chengweiting@whu.edu.cn
联系方式	027-88041911转82281或18062607220
研究方向	1.中药活性成分单体对肿瘤细胞能量代谢的影响及机制； 2.自噬在恶性肿瘤疾病进程中的调控作用及机制
个人简介	主要从事恶性肿瘤的诊治与科研工作，目前主持湖北省自然科学基金面上项目1项，湖北省自然科学青年基金1项，武汉市卫健委科研项目1项；参与国家自然科学基金2项，湖北省卫健委科研项目2项，在ASCO上发表重要研究成果2项，发表论文20余篇，其中SCI论文10余篇。目前已联合培养硕士生1名。
学术任职与荣誉	中德医学协会循证医学专委会常委中华中医药学会医药文化委员会委员湖北省临床肿瘤学会理事湖北省临床肿瘤学会肉瘤专家委员会副主任委员湖北省医学生物免疫学会肿瘤分会常委湖北省临床肿瘤学会青年专家委员会常委湖北省医师协会放射肿瘤治疗医师分会委员
教育履历	1999.09-2004.06华中科技大学同济医学院本科获学士学位 2004.09-2009.06华中科技大学同济医学院硕博连读获博士学位
工作履历	2009.07-2015.10华中科技大学同济医学院附属中西医结合医院肿瘤科主治医师 2015.10-2016.10德国慕尼黑大学肿瘤药物研究中心博士后研究 2016.10-2023.02华中科技大学同济医学院附属中西医结合医院肿瘤科副主任医师硕士生导师 2023.02-至今武汉大学人民医院肿瘤科副主任医师硕士生导师
成果获奖	2019年度卫生部《健康报》全国青年医生全明星计划50强《肺纤方对放射性肺炎的保护作用机制》获2011年武汉市科技成果奖
代表性论著	1.Pang L,Chen JZ,Xu D,Cheng WT. Casereport : Mycobacteriu neoauruminfection during ICI therapy in a hepatocellular carcinoma patient withwith psoriasis,Frontiers in Immunology.2022 22;13:972302. 2.Li X, Li M, Qiu H, Saad C, Zhao B, Li F, Wu X, Kuang D, Tang F, Chen Y, Shu H, Zhang J, Wang Q, Huang H, Qi S, Ye C, Bryant A, Yuan X, Kurts C, Hu G,Cheng W#, Mei Q#. Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes. Sci Rep. 2022, 12(1): 5070. 3.Li M,Cheng WT, Li H, Zhang Z,Lu XL,Deng SS,Li J,Yang CH. Comprehensive Analysis of Key mRNAs and lncRNAs in Osteosarcoma Response to Preoperative Chemotherapy with Prognostic Values. Curr Med Sci. 2021, 41(5): 916-929. 4.Cheng WT,Hornung R,Xu K,Yang CH,Li J. Complement C3 identified as an unique risk factor for disease severity among young COVID-19 patients in Wuhan, China. Sci Rep. 2021, 11(1): 7857. 5.Cheng WT, Ke YH,Yang GY, Sun H,Chen Y, Ying RY,Zeng XH,Shen D,Tang KJ,Xu K,Yu F. Analysis of clinical features of COVID-19 in cancer patients. Acta Oncol. 2020, 59(11): 1393-1396. 6.Cheng WT, Xiang W, Wang S, Kai Xu. Tanshinone IIA ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection and autophagy promotion. Am J Transl Res. 2019, 11(5): 3140-3149. 7.Cheng WT, Xu K, Tian DY, Zhang ZD, Liu LJ, Chen Y. Role of Hedgehog signaling pathway in proliferation and invasion of hepatocellular carcinoma. Int J Oncol. 2009, 34(3): 829-836. 8.Gleissner CM , Pyka CL, Heydenreuter W, Gronauer TF, Atzberger C, Cheng WT, Hacker SM, Vollmar AM, Braig S, Sieberet SA. Neocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways. ACS Cent Sci, 2019, 5(7): 1170-1178. 9.Xiang W, Guo F,Cheng WT, Zhang J, Huang J, Wang R, Ma Z, Xu K. HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia. Oncol Rep. 2017; 38(1):229-236. 10.Xiang W, Jiang T, Guo F, Xu T, Gong C, Cheng P, Zhao L,Cheng WT, Xu K. Evaluating the role of PTH in promotion of chondrosarcoma cell proliferation and invasion by inhibiting primary cilia expression. Int J Mol Sci. 2014, 15(11):19816-31. 11.Xiang W, Jiang T, Guo F, Gong C, Yang K, Wu Y, Huang X,Cheng WT, Xu K. Hedgehog pathway inhibitor-4 suppresses malignant properties of chondrosarcoma cells by disturbing tumor ciliogenesis. Oncol Rep. 2014; 32(4):1622-30.

Name	WEITING CHENG
Date of birth	March，1980
Department	Oncology of Department，Renmin Hospital,Wuhan University.
Title	Associate Chief Physician, Master Tutor Master tutor
Email	chengweiting@whu.edu.cn
TEL	027-88041911-86731 or 18062607220
Research Direction	1. Effect and mechanism of active ingredient monomer of traditional Chinese medicine on energy metabolism of tumor cells; 2. Regulatory role and mechanism of autophagy in the course of malignant tumor disease
Personal Profile	She is mainly engaged in the diagnosis and treatment of Cancer ,and has been awarded 2 items from the Provincia Natural Science Foundation, 1 item from the Wuhan Municipal Health Commission.More than 20 papers published by the first or corresponding author, including 10 SCI papers. By now,she has educated 1 masters.
Selected Publications	1.Pang L,Chen JZ,Xu D,Cheng WT. Casereport : Mycobacteriu neoauruminfection during ICI therapy in a hepatocellular carcinoma patient withwith psoriasis,Frontiers in Immunology.2022 22;13:972302. 2.Li X, Li M, Qiu H, Saad C, Zhao B, Li F, Wu X, Kuang D, Tang F, Chen Y, Shu H, Zhang J, Wang Q, Huang H, Qi S, Ye C, Bryant A, Yuan X, Kurts C, Hu G,Cheng W#, Mei Q#. Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes. Sci Rep. 2022, 12(1): 5070. 3.Li M, Cheng WT, Li H, Zhang Z,Lu XL,Deng SS,Li J,Yang CH. Comprehensive Analysis of Key mRNAs and lncRNAs in Osteosarcoma Response to Preoperative Chemotherapy with Prognostic Values. Curr Med Sci. 2021, 41(5): 916-929. 4.Cheng WT,Hornung R,Xu K,Yang CH,Li J. Complement C3 identified as an unique risk factor for disease severity among young COVID-19 patients in Wuhan, China. Sci Rep. 2021, 11(1): 7857. 5.Cheng WT, Ke YH,Yang GY, Sun H,Chen Y, Ying RY,Zeng XH,Shen D,Tang KJ,Xu K,Yu F. Analysis of clinical features of COVID-19 in cancer patients. Acta Oncol. 2020, 59(11): 1393-1396. 6.Cheng WT, Xiang W, Wang S, Kai Xu. Tanshinone IIA ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection and autophagy promotion. Am J Transl Res. 2019, 11(5): 3140-3149. 7.Cheng WT, Xu K, Tian DY, Zhang ZD, Liu LJ, Chen Y. Role of Hedgehog signaling pathway in proliferation and invasion of hepatocellular carcinoma. Int J Oncol. 2009, 34(3): 829-836. 8.Gleissner CM , Pyka CL, Heydenreuter W, Gronauer TF, Atzberger C, Cheng WT, Hacker SM, Vollmar AM, Braig S, Sieberet SA. Neocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways. ACS Cent Sci, 2019, 5(7): 1170-1178. 9.Xiang W, Guo F, Cheng WT, Zhang J, Huang J, Wang R, Ma Z, Xu K. HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia. Oncol Rep. 2017; 38(1):229-236. 10.Xiang W, Jiang T, Guo F, Xu T, Gong C, Cheng P, Zhao L, Cheng WT, Xu K. Evaluating the role of PTH in promotion of chondrosarcoma cell proliferation and invasion by inhibiting primary cilia expression. Int J Mol Sci. 2014, 15(11):19816-31. 11.Xiang W, Jiang T, Guo F, Gong C, Yang K, Wu Y, Huang X, Cheng WT, Xu K. Hedgehog pathway inhibitor-4 suppresses malignant properties of chondrosarcoma cells by disturbing tumor ciliogenesis. Oncol Rep. 2014; 32(4):1622-30.